{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:14:47Z","timestamp":1790835287347,"version":"4.1.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,6,18]],"date-time":"2013-06-18T00:00:00Z","timestamp":1371513600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1038\/nrrheum.2013.91","type":"journal-article","created":{"date-parts":[[2013,6,18]],"date-time":"2013-06-18T03:13:23Z","timestamp":1371525203000},"page":"513-523","source":"Crossref","is-referenced-by-count":245,"title":["Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm"],"prefix":"10.1038","volume":"9","author":[{"given":"Jamie","family":"Robertson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike J.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain B.","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,6,18]]},"reference":[{"key":"BFnrrheum201391_CR1","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1093\/rheumatology\/kep252","volume":"48","author":"C Meune","year":"2009","unstructured":"Meune, C., Touz\u00e9, E., Trinquart, L. & Allanore, Y. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 48, 1309\u20131313 (2009).","journal-title":"Rheumatology (Oxford)"},{"key":"BFnrrheum201391_CR2","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","volume":"71","author":"JA Avina-Zubieta","year":"2012","unstructured":"Avina-Zubieta, J. A., Thomas, J., Sasatsafavi, M., Lehman, A. J. & Lacaille, D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann. Rheum. Dis. 71, 1524\u20131529 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201391_CR3","doi-asserted-by":"crossref","unstructured":"Heart Protection Study Collaborative Group. MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360, 7\u201322 (2002).","DOI":"10.1016\/S0140-6736(02)09327-3"},{"key":"BFnrrheum201391_CR4","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","volume":"360","author":"J Shepherd","year":"2002","unstructured":"Shepherd, J.  et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360, 1623\u20131630 (2002).","journal-title":"Lancet"},{"key":"BFnrrheum201391_CR5","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.1161\/01.STR.0000147965.52712.fa","volume":"35","author":"P Amarenco","year":"2004","unstructured":"Amarenco, P., Labreuche, J., Lavall\u00e9e, P. & Touboul, P. J. Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis. Stroke 35, 2902\u20132909 (2004).","journal-title":"Stroke"},{"key":"BFnrrheum201391_CR6","doi-asserted-by":"crossref","unstructured":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288, 2998\u20133007 (2002).","DOI":"10.1001\/jama.288.23.2998"},{"key":"BFnrrheum201391_CR7","unstructured":"European Society of Cardiology. SCORE Risk Charts. The European cardiovascular disease risk assessment model \n                    [online]\n                    \n                  , (2012)."},{"key":"BFnrrheum201391_CR8","unstructured":"Scottish Intercollegiate Guidelines Network. ASSIGN score. Estimate the risk using ASSIGN score \n                    [online]\n                    \n                  , (2008)."},{"key":"BFnrrheum201391_CR9","unstructured":"ClinRisk Ltd. Welcome to the QRISK\u00ae2\u201312 risk calculator: \n                    http:\/\/qrisk.org\n                    \n                   \n                    [online]\n                    \n                  , (2012)."},{"key":"BFnrrheum201391_CR10","unstructured":"Framingham Heart Study. Risk Score Profiles \n                    [online]\n                    \n                  , (2013)."},{"issue":"18","key":"BFnrrheum201391_CR11","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2009.1619","volume":"302","author":"The Emerging Risk Factors Collabora","year":"2009","unstructured":"The Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302, 1993\u20132000 (2009).","journal-title":"JAMA"},{"key":"BFnrrheum201391_CR12","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","volume":"380","author":"B Voight","year":"2012","unstructured":"Voight, B.  et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380, 572\u2013580 (2012).","journal-title":"Lancet"},{"key":"BFnrrheum201391_CR13","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1161\/01.CIR.0000028423.07623.6A","volume":"106","author":"AS deLemos","year":"2002","unstructured":"deLemos, A. S., Wolfe, M. L., Long, C. J., Sivapackianathan, R. & Rader, D. J. Identification of genetic variants in endothelial lipase in persons with elevated high-density lipoprotein cholesterol. Circulation 106, 1321\u20131326 (2002).","journal-title":"Circulation"},{"key":"BFnrrheum201391_CR14","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1194\/jlr.R024075","volume":"53","author":"PJ Barker","year":"2012","unstructured":"Barker, P. J. & Rye, K. A. Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk. J. Lipid Res. 53, 1755\u20131766 (2012).","journal-title":"J. Lipid Res."},{"key":"BFnrrheum201391_CR15","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/BF02041560","volume":"2","author":"D Heldenberg","year":"1983","unstructured":"Heldenberg, D.  et al. Serum lipids and lipoprotein concentrations in women with rheumatoid arthritis. Clin. Rheumatol. 2, 387\u2013391 (1983).","journal-title":"Clin. Rheumatol."},{"key":"BFnrrheum201391_CR16","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/rheumatology\/24.3.250","volume":"24","author":"M Lorber","year":"1985","unstructured":"Lorber, M., Aviram, M., Linn, S., Scharf, Y. & Brook, J. G. Hypocholesterolaemia and abnormal high-density lipoprotein in rheumatoid arthritis. Br. J. Rheumatol. 24, 250\u2013255 (1985).","journal-title":"Br. J. Rheumatol."},{"key":"BFnrrheum201391_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0009-9120(88)80094-8","volume":"23","author":"J Lakatos","year":"1988","unstructured":"Lakatos, J. & H\u00e1rs\u00e1gyi, A. Serum total, HDL, LDL cholesterol, and triglyceridelevels in patients with rheumatoid arthritis. Clin. Biochem. 23, 93\u201396 (1988).","journal-title":"Clin. Biochem."},{"key":"BFnrrheum201391_CR18","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1136\/ard.53.8.551","volume":"53","author":"A Kavanaugh","year":"1994","unstructured":"Kavanaugh, A. Dyslipoproteinaemia in a subset of patients with rheumatoid arthritis. Ann. Rheum. Dis. 53, 551\u2013552 (1994).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201391_CR19","first-page":"1746","volume":"31","author":"WH Yoo","year":"2004","unstructured":"Yoo, W. H. Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles. J. Rheumatol. 31, 1746\u20131753 (2004).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201391_CR20","first-page":"1701","volume":"26","author":"YB Park","year":"1999","unstructured":"Park, Y. B.  et al. Lipid profiles in untreated patients with rheumatoid arthritis. J. Rheumatol. 26, 1701\u20131704 (1999).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201391_CR21","first-page":"U2125","volume":"119","author":"D White","year":"2006","unstructured":"White, D., Fayez, S. & Doube, A. Atherogenic lipid profiles in rheumatoid arthritis. N. Z. Med. J. 119, U2125 (2006).","journal-title":"N. Z. Med. J."},{"key":"BFnrrheum201391_CR22","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1002\/1529-0131(200112)44:12<2761::AID-ART463>3.0.CO;2-5","volume":"44","author":"E Hurt-Camejo","year":"2001","unstructured":"Hurt-Camejo, E.  et al. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum. 44, 2761\u20132767 (2001).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201391_CR23","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.3899\/jrheum.090639","volume":"37","author":"CP Chung","year":"2010","unstructured":"Chung, C. P.  et al. Lipoprotein subclasses determined by nuclear magnetic resonance spectroscopy and coronary atherosclerosis in patients with rheumatoid arthritis. J. Rheumatol. 37, 1633\u20131638 (2010).","journal-title":"J. Rheumatol."},{"key":"BFnrrheum201391_CR24","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1111\/j.1742-1241.2009.02220.x","volume":"64","author":"MJ Peters","year":"2010","unstructured":"Peters, M. J.  et al. The interplay between inflammation, lipids and cardiovascular risk in rheumatoid arthritis: why ratios may be better. Int. J. Clin. Prac. 64, 1440\u20131443 (2010).","journal-title":"Int. J. Clin. Prac."},{"key":"BFnrrheum201391_CR25","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1136\/ard.2006.051672","volume":"66","author":"VP van Halm","year":"2007","unstructured":"van Halm, V. P.  et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann. Rheum. Dis. 66, 184\u2013188 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201391_CR26","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1136\/ard.2009.122374","volume":"67","author":"E Myasoedova","year":"2010","unstructured":"Myasoedova, E.  et al. Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann. Rheum. Dis. 67, 1310\u20131314 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201391_CR27","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1136\/ard.2010.135871","volume":"70","author":"E Myasoedova","year":"2011","unstructured":"Myasoedova, E.  et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann. Rheum. Dis. 70, 482\u2013487 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201391_CR28","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1001\/jama.291.4.451","volume":"291","author":"Y Liu","year":"2004","unstructured":"Liu, Y.  et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 291, 451\u2013459 (2004).","journal-title":"JAMA"},{"key":"BFnrrheum201391_CR29","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1194\/jlr.R300019-JLR200","volume":"45","author":"W Khovidhunkit","year":"2004","unstructured":"Khovidhunkit, W.  et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J. Lipid Res. 45, 1169\u20131196 (2004).","journal-title":"J. Lipid Res."},{"key":"BFnrrheum201391_CR30","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1161\/01.ATV.14.1.8","volume":"14","author":"WH Ettinger","year":"1994","unstructured":"Ettinger, W. H.  et al. Cytokines decrease apolipoprotein accumulation in medium from Hep G2 cells. Arterioscler. Thromb. 14, 8\u201313 (1994).","journal-title":"Arterioscler. Thromb."},{"key":"BFnrrheum201391_CR31","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.cyto.2012.02.010","volume":"58","author":"M Hashizume","year":"2012","unstructured":"Hashizume, M. & Mihara, M. Atherogenic effects of TNF-\u03b1 and IL-6 via up-regulation of scavenger receptors. Cytokine 58, 424\u2013430 (2012).","journal-title":"Cytokine"},{"key":"BFnrrheum201391_CR32","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1097\/00075197-200203000-00006","volume":"5","author":"YA Carpentier","year":"2002","unstructured":"Carpentier, Y. A. & Scruel, O. Changes in the concentration and composition of plasma lipoproteins during the acute phase response. Curr. Opin. Clin. Nutr. Metab. Care 5, 153\u2013158 (2002).","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"BFnrrheum201391_CR33","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1161\/01.ATV.0000091338.93223.E8","volume":"23","author":"A Kontush","year":"2003","unstructured":"Kontush, A., Chantepie, S. & Chapman, M. J. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler. Thromb. Vasc. Biol. 23, 1881\u20131888 (2003).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"BFnrrheum201391_CR34","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/annrheumdis-2011-200493","volume":"71","author":"C Charles-Schoeman","year":"2012","unstructured":"Charles-Schoeman, C.  et al. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 71, 1157\u20131162 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201391_CR35","doi-asserted-by":"publisher","first-page":"R166","DOI":"10.1186\/ar3842","volume":"14","author":"E Arts","year":"2012","unstructured":"Arts, E.  et al. High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study. Arthritis Res. Ther. 14, R166 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201391_CR36","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1002\/art.34363","volume":"64","author":"J Watanabe","year":"2012","unstructured":"Watanabe, J.  et al. Proteomic profiling following immunoaffinity capture of high-density lipoprotein: association of acute-phase proteins and complement factors with proinflammatory high-density lipoprotein in rheumatoid arthritis. Arthritis Rheum. 64, 1828\u20131837 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201391_CR37","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s00296-004-0438-0","volume":"25","author":"D Dursunog\u02d8lu","year":"2005","unstructured":"Dursunog\u02d8lu, D.  et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol. Int. 25, 241\u2013245 (2005).","journal-title":"Rheumatol. Int."},{"key":"BFnrrheum201391_CR38","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","volume":"361","author":"R Clarke","year":"2009","unstructured":"Clarke, R.  et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N. Engl. J. Med. 361, 2518\u20132528 (2009).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201391_CR39","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/S0002-9343(02)01186-5","volume":"113","author":"YB Park","year":"2002","unstructured":"Park, Y. B.  et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. Am. J. Med. 113, 188\u2013193 (2002).","journal-title":"Am. J. Med."},{"key":"BFnrrheum201391_CR40","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1136\/ard.62.9.842","volume":"62","author":"M Boers","year":"2003","unstructured":"Boers, M.  et al. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann. Rheum. Dis. 62, 842\u2013845 (2003).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201391_CR41","doi-asserted-by":"publisher","first-page":"R32","DOI":"10.1186\/ar1952","volume":"8","author":"AN Georgiadis","year":"2006","unstructured":"Georgiadis, A. N.  et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment\u2014a prospective, controlled study. Arthritis Res. Ther. 8, R32 (2006).","journal-title":"Arthritis Res. Ther."},{"key":"BFnrrheum201391_CR42","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.1002\/art.24040","volume":"58","author":"AB Reiss","year":"2008","unstructured":"Reiss, A. B.  et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte\/macrophages. Arthritis Rheum. 58, 3675\u20133683 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201391_CR43","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1136\/ard.56.6.374","volume":"56","author":"R Munro","year":"1997","unstructured":"Munro, R.  et al. Effect of disease modifying agents on the lipid profiles of patients with rheumatoid arthritis. Ann. Rheum. Dis. 56, 374\u2013377 (1997).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201391_CR44","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/acr.20393","volume":"63","author":"SJ Morris","year":"2011","unstructured":"Morris, S. J.  et al. Hydroxychloroquine use associated with improvement in lipid profiles in rheumatoid arthritis patients. Arthritis Care Res. 63, 530\u2013534 (2011).","journal-title":"Arthritis Care Res."},{"key":"BFnrrheum201391_CR45","doi-asserted-by":"publisher","unstructured":"Navarro-Mill\u00e1n, I.  et al. Changes in lipoproteins associated with treatment with methotrexate or combination therapy in early rheumatoid arthritis: results from the TEAR trial. Arthritis Rheum. \n                    http:\/\/dx.doi.org\/10.1002\/art.37916\n                    \n                  .","DOI":"10.1002\/art.37916"},{"key":"BFnrrheum201391_CR46","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1136\/ard.2006.062497","volume":"66","author":"LT Jacobsson","year":"2007","unstructured":"Jacobsson, L. T.  et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann. Rheum. Dis. 66, 670\u2013675 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201391_CR47","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1002\/art.22809","volume":"56","author":"WG Dixon","year":"2007","unstructured":"Dixon, W. G.  et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor \u03b1 therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum. 56, 2905\u20132912 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201391_CR48","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.semarthrit.2011.04.003","volume":"41","author":"AM van Sijl","year":"2011","unstructured":"van Sijl, A. M.  et al. The effect of TNF-\u03b1 blocking therapy on lipid levels in rheumatoid arthritis: a meta-analysis. Semin. Arthritis Rheum. 41, 393\u2013400 (2011).","journal-title":"Semin. Arthritis Rheum."},{"key":"BFnrrheum201391_CR49","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1136\/annrheumdis-2011-201148","volume":"71","author":"CI Da\u00efen","year":"2012","unstructured":"Da\u00efen, C. I.  et al. Effect of TNF inhibitors on lipid profile in rheumatoid arthritis: a systematic review with meta-analysis. Ann. Rheum. Dis. 71, 862\u2013868 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201391_CR50","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cca.2005.08.010","volume":"365","author":"Y Allanore","year":"2006","unstructured":"Allanore, Y., Kahan, A., Sellam, J., Ekindjian, O. G. & Borderie, D. Effects of repeated infliximab therapy on serum lipid profile in patients with refractory rheumatoid arthritis. Clin. Chim. Acta 365, 143\u2013148 (2006).","journal-title":"Clin. Chim. Acta"},{"key":"BFnrrheum201391_CR51","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1136\/ard.2006.066191","volume":"66","author":"C Popa","year":"2007","unstructured":"Popa, C.  et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 66, 1503\u20131507 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201391_CR52","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s10067-007-0539-8","volume":"26","author":"LS Tam","year":"2007","unstructured":"Tam, L. S., Tomlinson, B., Chu, T. T., Li, T. K. & Li, E. K. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin. Rheumatol. 26, 1495\u20131498 (2007).","journal-title":"Clin. Rheumatol."},{"key":"BFnrrheum201391_CR53","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/art.24492","volume":"60","author":"IC van Eijk","year":"2009","unstructured":"van Eijk, I. C.  et al. Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade. Arthritis Rheum. 60, 1324\u20131330 (2009).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201391_CR54","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1136\/ard.2008.092171","volume":"68","author":"C Popa","year":"2009","unstructured":"Popa, C.  et al. Anti-inflammatory therapy with tumour necrosis factor \u03b1 inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann. Rheum. Dis. 68, 868\u2013872 (2009).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201391_CR55","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1002\/art.22447","volume":"56","author":"N Sattar","year":"2007","unstructured":"Sattar, N.  et al. Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: a double-blind, placebo-controlled study. Arthritis Rheum. 56, 831\u2013839 (2007).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201391_CR56","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/ard.2006.068064","volume":"66","author":"N Nishimoto","year":"2007","unstructured":"Nishimoto, N.  et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x-ray reader-blinded randomised controlled trial of tocilizumab. Ann. Rheum. Dis. 66, 1162\u20131167 (2007).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201391_CR57","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/ard.2008.105197","volume":"69","author":"G Jones","year":"2010","unstructured":"Jones, G.  et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann. Rheum. Dis. 69, 88\u201396 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201391_CR58","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1002\/art.22033","volume":"54","author":"RN Maini","year":"2006","unstructured":"Maini, R. N.  et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 54, 2817\u20132819 (2006).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201391_CR59","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/S0140-6736(08)60453-5","volume":"371","author":"JS Smolen","year":"2008","unstructured":"Smolen, J. S.  et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371, 987\u2013997 (2008).","journal-title":"Lancet"},{"key":"BFnrrheum201391_CR60","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1002\/art.23940","volume":"58","author":"MC Genovese","year":"2008","unstructured":"Genovese, M. C.  et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 58, 2968\u20132980 (2008).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201391_CR61","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3109\/s10165-010-0366-7","volume":"21","author":"H Yamanaka","year":"2011","unstructured":"Yamanaka, H.  et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod. Rheumatol. 21, 122\u2013133 (2011).","journal-title":"Mod. Rheumatol."},{"key":"BFnrrheum201391_CR62","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1136\/ard.2010.139725","volume":"70","author":"GR Burmester","year":"2011","unstructured":"Burmester, G. R.  et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann. Rheum. Dis. 70, 755\u2013759 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201391_CR63","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1136\/ard.2010.148700","volume":"71","author":"Y Yazici","year":"2012","unstructured":"Yazici, Y.  et al. Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study. Ann. Rheum. Dis. 71, 198\u2013205 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201391_CR64","doi-asserted-by":"publisher","unstructured":"Gabay, C.  et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet \n                    http:\/\/dx.doi.org\/10.1016\/S0140\u20136736(13)60250\u20130\n                    \n                  .","DOI":"10.1016\/S0140-6736(13)60250-0"},{"key":"BFnrrheum201391_CR65","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","volume":"379","author":"AS Hingorani","year":"2012","unstructured":"Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6 MR) Consortium, Hingorani, A. S. & Casas, J. P. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 379, 1214\u20131224 (2012).","journal-title":"Lancet"},{"key":"BFnrrheum201391_CR66","doi-asserted-by":"crossref","unstructured":"IL6R Genetics Consortium Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 379, 1205\u20131213 (2012).","DOI":"10.1016\/S0140-6736(11)61931-4"},{"key":"BFnrrheum201391_CR67","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s10067-009-1095-1","volume":"28","author":"G Kerekes","year":"2009","unstructured":"Kerekes, G.  et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin. Rheumatol. 28, 705\u2013710 (2009).","journal-title":"Clin. Rheumatol."},{"key":"BFnrrheum201391_CR68","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1136\/annrheumdis-2011-201228","volume":"72","author":"HG Raterman","year":"2013","unstructured":"Raterman, H. G.  et al. HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. Ann. Rheum. Dis. 72, 560\u2013565 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201391_CR69","unstructured":"US Department of Health & Human Services. US Food and Drug Administration News Release: FDA approves Xeljanz for rheumatoid arthritis \n                    [online]\n                    \n                  , (2012)."},{"key":"BFnrrheum201391_CR70","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann, R.  et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N. Engl. J. Med. 367, 495\u2013507 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201391_CR71","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven, R. F.  et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N. Engl. J. Med. 367, 508\u2013519 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201391_CR72","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1056\/NEJMoa1112168","volume":"367","author":"WJ Sandborn","year":"2012","unstructured":"Sandborn, W. J.  et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N. Engl. J. Med. 367, 616\u2013624 (2012).","journal-title":"N. Engl. J. Med."},{"key":"BFnrrheum201391_CR73","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1002\/art.33419","volume":"64","author":"J Kremer","year":"2012","unstructured":"Kremer, J.  et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 64, 970\u2013981 (2012).","journal-title":"Arthritis Rheum."},{"key":"BFnrrheum201391_CR74","unstructured":"ISRCTN Register. TRial of Atorvastatin for the primary prevention of Cardiovascular Events in Rheumatoid Arthritis \n                    [online]\n                    \n                  , (2008)."},{"key":"BFnrrheum201391_CR75","unstructured":"US NIH. US National Library of Medicine. A study of roactemra\/actemra (tocilizumab) in comparison to etanercept in patients with rheumatoid arthritis and cardiovascular disease risk factors \n                    [online]\n                    \n                  , (2013)."},{"key":"BFnrrheum201391_CR76","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1136\/ard.2009.113696","volume":"69","author":"MJ Peters","year":"2010","unstructured":"Peters, M. J.  et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann. Rheum. Dis. 69, 325\u2013331 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"BFnrrheum201391_CR77","unstructured":"Kwaliteitsinstituut voor de Gezondheidszorg CBO & Nederlands Huisartsen Genootschap (NHG). Multidisciplinaire richtlijn cardiovasculair risicomanagement, herziening 2011 \n                    [online; Dutch]\n                    \n                  , (2011)."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2013.91.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2013.91","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrrheum.2013.91.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:33:52Z","timestamp":1684456432000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrrheum.2013.91"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6,18]]},"references-count":77,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["BFnrrheum201391"],"URL":"https:\/\/doi.org\/10.1038\/nrrheum.2013.91","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,18]]}}}